Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets

Journal of Pharmaceutical Sciences

Volumn 102, Issue 4, 2013, Pages 1370-1381

  Yang, Yongsheng ^a   Bykadi, Srikant ^a   Carlin, Alan S ^a   Shah, Rakhi B ^a   Yu, Lawrence X ^a   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Analysis; Bioavailability; Bioequivalence; Chromatography; in vitro models; Kinetics; Pharmacokinetics

Indexed keywords

LANTHANUM CARBONATE; PHOSPHATE;

ARTICLE; BINDING KINETICS; CHEWABLE TABLET; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; IN VITRO STUDY; PH;

EID: 84874726141     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23454     Document Type: Article

References (33)

1. Berner YN, Shike M. 1988. Consequences of phosphate imbalance. Annu Rev Nutr 8(1):121-148.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. 1998. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31(4):607-617.
3. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. 2000. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342(20):1478-1483.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. 2004. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15(8):2208-2218.
5. Coladonato JA. 2005. Control of hyperphosphatemia among patients with ESRD. J Am Soc Nephrol 16 Suppl 2:107-114.
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. 2009. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76 Suppl 113:1-130.
7. Loghman-Adham M. 1999. Phosphate binders for control of phosphate retention in chronic rental failure. Pediatr Nephrol 13(8):701-708.
8. McIntyre CW. 2007. New developments in the management of hyperphosphatemia in chronic kidney disease. Semin Dial 20(4):337-341.
9. Alfrey AC, LeGendre GR, Kaehny WD. 1976. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294(4):184-188.
10. Bellasi A, Kooienga L, Block GA. 2006. Phosphate binders: New products and challenges. Hemodial Int 10(3):225-234.
11. Slatopolsky E, Weerts C, Lopez-Hiker S, Norwood K, Zink M, Windus D, Delmez J. 1986. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315(3):157-161.
12. Braun J, Asmus HG, Holzer H, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J. 2004. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 62(2):104-115.
13. Albaaj F, Hutchison AJ. 2005. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. Expert Opin Pharmacother 6(2):319-328.
14. Pai AB, Conner TA, McQuade CR. 2009. Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opin Drug Metab 5(1):71-81.
15. Wrong O, Harland C. 2007. Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. Nephron Physiol 107(1):17-33.
16. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, Manns B. 2007. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transpl 22(10):2856-2866.
17. Sprague SM. 2007. A comparative review of the efficacy and safety of established phosphate binders: Calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin 23(12):3167-3175.
18. Martin P, Wang P, Robinson A, Poole L, Dragone J, Smyth M, Pratt R. 2011. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: A balance study. Am J Kidney Dis 57(5):700-706.
19. Behets GJ, Verberckmoes SC, Haese PC, De Broe ME. 2004. Lanthanum carbonate: A new phosphate binder. Curr Opin Nephrol Hypertens 13(4):403-409.
20. Damment SJ, Pennick M. 2008. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. J Clin Pharmacokinet 47(9):553-563.
21. Pennick M, Dennis K, Damment SJ. 2006. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharmacokinet 46(7):738-746.
22. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. 1989. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 83(1):66-73.
23. Gessner PK, Hasan MM. 1987. Freundlich and Langmuir isotherms as models for the adsorption of toxicants on activated charcoal. J Pharm Sci 76(4):319-327.
24. Motulsky HJ. Intuitive biostatistics. Oxford, UK: Oxford University Press, pp 285-286.
25. Samy R, Faustino PJ, Adams W, Yu L, Khan MA, Yang Y. 2010. Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonate. J Pharm Biomed Anal 51(5):1108-1112.
26. Food and Drug Administration, Center for Drug Evaluation and Research. 2001. Guidance for industry-Bioanalytical method validation. Rockville, Maryland: US FDA.
27. Houghton LA., Mangnall YF, Read NW. 1990. Effect of incorporating fat into a liquid test meal on the relation between intragastric distribution and gastric emptying in human volunteers. Gut 31(11):1226-1229.
28. Read NW, Miles CA, Fischer D, Halgate AM, Konie ND, Mitchell MA, Reeve AM, Roche TB, Walker M. 1980. Transit of a meal through the stomach, small intestine and colon in normal subjects and its role in the pathogenesis of diarrhea. Gastroenterology 79(6):1276-1282.
29. Shire Canada Inc. 2010. Product monograph: Fosrenol (lanthanum carbonate hydrate). Accessed March 8, 2012, at: http://www.shirecanada.com/en/shire-canada/Fosrenol_M_100203_En.pdf.
30. Autissier V, Dammen SJ, Henderson RA. 2007. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 96(10):2818-2827.
31. Fleisher D, Li C, Zhou YJ, Pao LH, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration-Clinical implications. Clin Pharmacokinet 36(3):233-254.
32. Davis GR, Zerwekh JE, Parker TF, Krejs GJ, Pak CTC, Fordtran JS. 1983. Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of Vitamin D deficiency. Gastroenterology 85(4):908-916.
33. Hruska KA, Mathew S, Lund R, Qiu P, Pratt P. 2008. Hyperphosphatemia of chronic kidney disease. Kidney Int 74(2):148-157.